Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Myungmoon Pharm Co., Ltd. (017180:KRX), powered by AI.
Myungmoon Pharm Co., Ltd. is currently trading at ₩1,320. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Myungmoon Pharm Co., Ltd. on Alpha Lenz.
Myungmoon Pharm Co., Ltd.'s P/E ratio is 23.6.
“Myungmoon Pharm Co., Ltd. trades at a P/E of 23.6 (fair value) with modest ROE of 1.9%.”
Ask for details →Myungmoon Pharm Co., Ltd. is a pharmaceutical company that plays a significant role in the healthcare and medical sectors. The primary function of Myungmoon Pharm is to research, develop, and market various pharmaceutical products ranging from prescription medications to over-the-counter remedies. The company is committed to advancing medical science and improving patient care by delivering innovative and effective health solutions. Myungmoon Pharm focuses on a diverse array of therapeutic areas, including cardiovascular health, metabolic disorders, and central nervous system conditions, among others. The company's operations extend beyond domestic borders, impacting global healthcare through international partnerships and distribution networks. By leveraging advanced research methodologies and cutting-edge technology, Myungmoon Pharm is at the forefront of pharmaceutical innovation. In the financial markets, Myungmoon Pharm Co., Ltd. holds significance due to its contributions to the rapidly evolving pharmaceutical industry. Investors and analysts closely watch the company's developments, as they may influence both healthcare advancements and market dynamics. With its dedication to improving healthcare outcomes, Myungmoon Pharm Co., Ltd. remains a pivotal entity in the pharmaceutical landscape.
“Myungmoon Pharm Co., Ltd. trades at a P/E of 23.6 (fair value) with modest ROE of 1.9%.”
Ask for details →Myungmoon Pharm Co., Ltd. (ticker: 017180) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 291 employees. Market cap is $44.8B.
The current price is ₩1,320 with a P/E ratio of 23.65x and P/B of 0.45x.
ROE is 1.94% and operating margin is 3.50%. Annual revenue is $195.2B.